OC
NVO

Opinicus Capital’s Novo Nordisk NVO Stock Holding History

Opinicus Capital’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-4,024
Closed -$278K – 113
2025
Q2 		$278K Sell
4,024
-569
-12% -$38.7K 0.21% 87
2025
Q1 		$319K Buy
4,593
+1,054
+30% +$87.1K 0.28% 82
2024
Q4 		$304K Sell
3,539
-448
-11% -$48.4K 0.26% 80
2024
Q3 		$475K Sell
3,987
-825
-17% -$110K 0.38% 67
2024
Q2 		$687K Sell
4,812
-6
-0.1% -$795 0.58% 51
2024
Q1 		$619K Buy
+4,818
New +$574K 0.55% 56

Other funds holding NVO

Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return
Fayez Sarofim & Co
Fayez Sarofim & Co Houston, Texas $39.1B AUM 15.14% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Opinicus Capital's NVO Position: Q3 2025 in Review

Opinicus Capital sold out of Novo Nordisk (NVO) in Q3 2025, closing a stake of 4,024 shares — an estimated $278K sold.

Opinicus Capital first reported a position in NVO in Q1 2024 and held it in 6 quarters. The position peaked at $687K in Q2 2024. 1,395 funds tracked by Wall St. Rank hold NVO as of Q3 2025.

  • Opinicus Capital reported no remaining Novo Nordisk position as of Q3 2025 after selling out during the quarter.
  • Opinicus Capital sold 4,024 Novo Nordisk shares in Q3 2025, an estimated $278K.
  • Opinicus Capital first reported a position in Novo Nordisk in Q1 2024 and held it in 6 quarters.
  • Opinicus Capital's Novo Nordisk position peaked at $687K in Q2 2024.
  • 1,395 funds tracked by Wall St. Rank held Novo Nordisk as of Q3 2025.

Based on Opinicus Capital's 13F filing for Q3 2025, filed 6 Nov 2025.